通过局部特异性抗体与曼诺6-酸盐甘氨酸结合的向蛋白质降解
Kaori Mukai1, Robert Cost2, Xin Sheen Zhang3
1Immunology & Inflammation Research, Sanofi, Cambridge, MA, USA.
mAbs
|October 22, 2024
概括
我们开发了一种新型的抗体结合方法,用于创建色素向化马 (LYTACs),用于向蛋白质降解. 这种方法有效地针对TNF等细胞外蛋白进行 lysosomal 降解,从而提供了新的治疗可能性.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 有针对性的蛋白质降解为消除细胞外蛋白质提供了新的治疗策略.
- lysosome-targeting Chimera (LYTACs) 使用曼诺6酸盐受体 (M6PR) 来有效降解目标蛋白质的 lysosomal 降解.
- 现有的抗体结合方法通常需要化学酶修改.
研究的目的:
- 开发一种新的,局部特定的抗体结合方法,用于产生抗体曼诺6酸盐 (M6P) 结合物.
- 评估这些结合物在通过内溶酶体通路准和降解细胞外蛋白的效率.
- 建立一个平台,为潜在的疾病治疗创造基于生物的降解剂.
主要方法:
- 产生一个Fc工程抗体 (NNAS) 与一个转移的糖基化位点 (Asn298) 增强的化.
- 合成M6P甘氨酸 (bisM6P) 与工程抗体甘氨酸的酸的特定位点结合,无需化学酶修饰.
- 使用质谱学对联同质性的分析.
- 在实验室中评估M6P结合抗体在癌症和免疫细胞中内化和降解人类瘤亡因子 (TNF) 的疗效,使用共聚焦显微镜和流细胞计.
主要成果:
- 开发的方法产生了同质的抗体-M6P结合物,通常有一个或两个结合的甘氨酸.
- 这种M6P结合抗体通过内溶性酶体路径在癌症和免疫细胞中有效地内化可溶性TNF.
- 在细胞培养基中观察到TNF显著减少,由M6PR调解,与细胞表面CI-MPR表达相关.
- 内化TNF在溶酶体中被有效降解.
结论:
- 这种新型抗体-M6P结合平台能够有效地生成特定地点的LYTACs.
- 这种方法促进了细胞外蛋白的有针对性的内化和 lysosome-mediated 降解.
- 开发的基于生物的降解剂有望通过事件驱动的药理学来治疗疾病,并解决未满足的医疗需求.
更多相关视频
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
7.7K
08:47Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
9.4K
相关概念视频
Regulated Protein Degradation
7.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.2K
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
The Proteasome
8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
Export of Misfolded Proteins out of the ER
3.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.5K
